These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bayer to settle lawsuits over Baycol. Health News; 2004 Sep; 10(9):2. PubMed ID: 15597437 [No Abstract] [Full Text] [Related]
5. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". Piorkowski JD JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725 [No Abstract] [Full Text] [Related]
6. How a statin might destroy a drug company. Lancet; 2003 Mar; 361(9360):793. PubMed ID: 12642039 [No Abstract] [Full Text] [Related]
7. Bayer is forced to release documents over withdrawal of cerivastatin. Marwick C BMJ; 2003 Mar; 326(7388):518. PubMed ID: 12623898 [No Abstract] [Full Text] [Related]
8. Substituting for cerivastatin (Baycol). Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579 [No Abstract] [Full Text] [Related]
9. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
10. [After recall of cerivastatin. How safe are statins in reality? (interview by Dr. Dirk Einecke)]. Schwandt P MMW Fortschr Med; 2001 Aug; 143(33-34):12. PubMed ID: 11561452 [No Abstract] [Full Text] [Related]
11. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751 [TBL] [Abstract][Full Text] [Related]
12. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. Strom BL JAMA; 2004 Dec; 292(21):2643-6. PubMed ID: 15572722 [No Abstract] [Full Text] [Related]
13. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil]. Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824 [TBL] [Abstract][Full Text] [Related]
14. Cerivastatin and the dissemination of adverse event information. Weaver SJ; Doering PL Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704 [No Abstract] [Full Text] [Related]
17. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Alsheikh-Ali AA; Karas RH Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929 [TBL] [Abstract][Full Text] [Related]
18. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. McAdams M; Staffa J; Dal Pan G Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291 [TBL] [Abstract][Full Text] [Related]
19. Rhabdomyolysis and cerivastatin: was it a problem of dose? Kalaria D; Wassenaar W CMAJ; 2002 Oct; 167(7):737. PubMed ID: 12389822 [No Abstract] [Full Text] [Related]
20. Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs. Harv Heart Lett; 2005 Sep; 16(1):3. PubMed ID: 16211723 [No Abstract] [Full Text] [Related] [Next] [New Search]